Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Colorcon
Baxter
Harvard Business School
Moodys

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Sparc Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Sparc
International Patents:23
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Sparc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes 8,425,938   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes 8,470,367   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No 8,431,156   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No 8,470,367   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes 8,535,717   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No 8,163,306   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No 8,425,938   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Sparc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0162036 2000C/032 Belgium   Start Trial PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
0162036 C300028 Netherlands   Start Trial PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Harvard Business School
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.